Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS TMPRSS6-LRx

  • STATUS
    Recruiting
  • End date
    Oct 28, 2022
  • participants needed
    36
  • sponsor
    Ionis Pharmaceuticals, Inc.
Updated on 28 January 2021
Investigator
Ionis Pharmaceuticals
Primary Contact
Chronic Care Center (3.3 mi away) Contact
+24 other location

Summary

The purpose is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of IONIS TMPRSS6-LRx administered subcutaneously to participants with non-transfusion dependent -Thalassemia Intermedia.

Description

This is a multi-center, randomized, open-label study in up to 45 participants. The duration of each participant in the study will be approximately 29 months and will include an approximately 2-month screening period, a 24-month treatment period, and a 3-month post-treatment period.

Details
Condition Beta Thalassemia Intermedia
Treatment IONIS TMPRSS6-Lrx
Clinical Study IdentifierNCT04059406
SponsorIonis Pharmaceuticals, Inc.
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willingness to comply with study procedures
Clinical diagnosis of Beta-Thalassemia Intermedia with genotypic confirmation
Non-transfusion dependent, as defined by: no more than 6 transfusions in the past 12-month period, and no transfusions in the 8-week period prior to Day 1
Mean Hb within the range of 6.0-10.0 g/dL, inclusive at Screening
LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive
If using chelators, must be on a stable dose for at least 3 months with LIC > 5.0 mg Fe/g dry weight and serum ferritin > 300 nanograms per milliliter (ng/mL)
Females must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal
Males must be surgically sterile, abstinent or using an acceptable contraceptive method

Exclusion Criteria

Clinically significant abnormalities in lab values, medical history, or physical examination
globin gene triplication
Symptomatic splenomegaly
Platelet count < lower limit of normal (LLN) or > 1,000 x 10^9/L
Significant concurrent/recent coagulopathy, history of non-traumatic significant bleeding; history of immune thrombocytopenic purpura (ITP); current use of SC anti-coagulants; history of thrombotic events, including stroke or DVT
Clinically significant renal, liver or cardiac dysfunction
Uncontrolled hypertension (> 140 mm Hg systolic or > 90 mm Hg diastolic)
Fasting blood glucose > 2.0 upper limit of normal (ULN)
Inability to have a magnetic resonance imaging (MRI) scan
Known history or positive test for human immunodeficiency virus (HIV), hepatitis C (HCV), or hepatitis B (HBV)
Active infection requiring systemic antiviral or antimicrobial therapy
Regular excessive use of alcohol
Recent start of hydroxyurea (6 months prior to Day 1)
Treatment with or recent exposure to another investigational drug, biological agent, ASO, small interfering ribonucleic acid (siRNA), or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment with or exposure to
sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of Screening
hematopoietic stimulating agents or any hypoxia-inducible factor prolyl hydroxylase inhibitors within 8 weeks of Day 1
prior bone marrow transplant, stem cell transplant, or gene therapy
Surgery associated with significant blood loss within 4 months of Screening, splenectomy within 12 months of Screening, or splenectomy scheduled during treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note